Results from lecanemab drug study hailed as ‘historic moment’ for Alzheimer’s treatment
An experimental drug has slowed the rate of decline in memory and thinking in people with early Alzheimer’s disease in what is being described as a “historic moment” for dementia treatment.
In the first phase 3 trial to unambiguously slow cognitive decline in Alzheimer’s, patients given the drug, developed by Eisai and Biogen, declined by 27% less than those on a placebo treatment after 18 months. This is a modest change in clinical outcome but it is the first time any drug has been clearly shown to alter the disease’s trajectory.
Subscribe
Login
0 Comments